Inhibrx (NASDAQ:INBX) Receives Market Perform Rating from JMP Securities

JMP Securities reaffirmed their market perform rating on shares of Inhibrx (NASDAQ:INBX) in a report published on Thursday,Benzinga reports.

Inhibrx Stock Performance

NASDAQ INBX opened at $12.33 on Thursday. Inhibrx has a one year low of $10.80 and a one year high of $34.71. The stock’s 50 day simple moving average is $12.64 and its 200 day simple moving average is $13.65.

Inhibrx (NASDAQ:INBX) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($2.80) EPS for the quarter, missing analysts’ consensus estimates of ($2.55) by ($0.25). As a group, equities research analysts forecast that Inhibrx will post 104.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Inhibrx

A number of large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its position in Inhibrx by 2.6% during the 1st quarter. Bank of New York Mellon Corp now owns 52,800 shares of the company’s stock worth $739,000 after acquiring an additional 1,355 shares during the last quarter. PNC Financial Services Group Inc. acquired a new position in Inhibrx during the 4th quarter worth $28,000. Natixis acquired a new position in Inhibrx during the 4th quarter worth $31,000. JPMorgan Chase & Co. lifted its holdings in Inhibrx by 47.8% during the 4th quarter. JPMorgan Chase & Co. now owns 7,592 shares of the company’s stock worth $117,000 after buying an additional 2,457 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Inhibrx during the 4th quarter worth $47,000. 82.46% of the stock is currently owned by institutional investors.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.